Aprea Therapeutics Stock (NASDAQ:APRE)
Previous Close
$3.90
52W Range
$2.15 - $8.85
50D Avg
$3.42
200D Avg
$3.90
Market Cap
$20.16M
Avg Vol (3M)
$24.80K
Beta
1.74
Div Yield
-
APRE Company Profile
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
APRE Performance
Peer Comparison
| Ticker | Company |
|---|---|
| MLYS | Mineralys Therapeutics, Inc. |
| APM | Aptorum Group Limited |
| SRZN | Surrozen, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| SILO | Silo Pharma, Inc. |
| ANAB | AnaptysBio, Inc. |
| RZLT | Rezolute, Inc. |
| TPST | Tempest Therapeutics, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| IKNA | Ikena Oncology, Inc. |
| RNXT | RenovoRx, Inc. |
| GBIO | Generation Bio Co. |
| FBRX | Forte Biosciences, Inc. |
| UNCY | Unicycive Therapeutics, Inc. |